BioCentury
ARTICLE | Company News

Ambrx, Astellas in ADC cancer deal

April 5, 2013 11:07 PM UTC

Ambrx Inc. (La Jolla, Calif.) partnered with Astellas Pharma Inc. (Tokyo:4503) to discover and develop antibody-drug conjugates (ADCs) for undisclosed cancer indications. Ambrx will receive $15 million up front and is eligible for up to $285 million in milestones, plus royalties. Ambrx will use its EuCODE site-specific protein chemistry technology to design and develop ADCs against undisclosed targets selected by Astellas, and Astellas will have worldwide rights to develop and commercialize the ADCs for cancer. ...